resTORbio to Present at the Deutsche Bank 43rd Annual Health Care Conference

BOSTON, May 01, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. TORC, a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that company management will present a corporate overview at the Deutsche Bank 43^rd Annual Health Care Conference on Tuesday, May 8, 2018 at 4:10 p.m. ET in Boston.

A live webcast of the presentation can be accessed on the Investors section of resTORbio's website at http://ir.restorbio.com/investors.

About resTORbio

resTORbio, Inc. is a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio's lead program is targeting the selective inhibition of TORC1 - an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac and neurologic systems. RTB101, resTORbio's lead drug candidate, is a selective, orally administered, TORC1 inhibitor currently being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. The company expects to develop RTB101 for additional aging-related indications such as heart failure or neurodegenerative diseases. 

Contacts:

Beth DelGiacco

Stern Investor Relations, Inc.

212-362-1200

beth@sternir.com

Michael Lampe

Scient PR

484-575-5040

michael@scientpr.com